1. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter 
Joe B Putnam, MD, Garrett L Walsh, MD, Stephen G Swisher, MD, Jack A Roth, MD, Douglas M Suell, MD, Ara A Vaporciyan, MD, W.Roy Smythe, MD, Kelly W Merriman, MS, Linda L DeFord, MS 
The Annals of Thoracic Surgery 
Volume 69, Issue 2, Pages (February 2000)
DOI: /S (99)

2. Fig 1
Overall survival for all patients with malignant pleural effusion (n = 168). Median survival is 3.48 months.
The Annals of Thoracic Surgery  , DOI: ( /S (99) )

3. Fig 2
Survival in MPE by histology. Primary histology shown as lung (circles), breast (squares), other (triangles), or lymphoma (vertical lines). Censored patients are shown. Median survival for lung cancer patients (n = 61) was 2.07 ± 0.71 months, for breast cancer (n = 39) was 4.50 ± 1.27 months, for other histology (n = 56) was 4.14 ± 1.73 months, and for lymphoma, median was not reached at 48 months (p = log rank; p = Breslow).
The Annals of Thoracic Surgery  , DOI: ( /S (99) )

4. Fig 3
Survival in MPE by treatment group. Treatment groups are shown inpatient CT (circles), as inpatient PC (squares), or outpatient PC (triangles). Censored patients are shown. Median survival for inpatient CT (n = 68) was 2.24 ± 0.72 (95% confidence interval 0.83 to 3.64), for inpatient PC (n = 40) was 2.66 ± 0.89 (95% confidence interval 0.92 to 4.40), and for outpatient PC (n = 60) was 5.85 ± 2.67 (95% confidence interval 0.62 to 11.08) (p = log-rank; p = Breslow).
The Annals of Thoracic Surgery  , DOI: ( /S (99) )